Lactobacillus delbrueckii subsp. lactis CKDB001 Attenuates Hepatic Steatosis and Metabolic Dysfunction in High-Fat Diet-Induced Obese Mice.

Authors

Jisu Lee, Minseo Cho, Jaeryang Chu, Yeon-Woo Kim, Jiwoo Lee, Yoo Jin Kwon, Chang Hun Shin, Hyunchae Joung, Jung-Heun Ha

Published in

Journal of medicinal food. Pages 1096620X261500242. Oct 20, 2026. Epub Oct 20, 2026.

Abstract

Metabolic dysfunction associated with obesity frequently coincides with hepatic lipid accumulation; however, effective preventive strategies are scarce. This study evaluated the dose-dependent effects of Lactobacillus delbrueckii subsp. lactis CKDB001 in mice with high-fat diet (HFD)-induced obesity. Male C57BL/6J mice were assigned to a normal diet, HFD, or HFD with CKDB001 at one of three different doses (LL1, 5.0 × 10⁸; LL2, 1.0 × 10⁹; LL3, 5.0 × 10⁹ CFU/day). Following 4 weeks of HFD feeding, CKDB001 was administered daily for 8 weeks while maintaining the HFD. Among the doses, LL2 demonstrated the most consistent outcomes, including reductions in body weight gain and liver and adipose tissue weights, without affecting food or energy intake. LL2 also decreased serum total cholesterol, alanine aminotransferase levels, hepatic cholesterol content, and histological scores for steatosis, fibrosis, and nonalcoholic fatty liver disease. Although changes in hepatic triglyceride and lipid metabolism-related gene expression were minimal, LL2 and LL3 enhanced colonic Zo-1 and occludin mRNA expression compared to the HFD group, suggesting a potential gut-associated transcriptional response to CKDB001 supplementation.

PMID:
42902585
Bibliographic data and abstract were imported from PubMed on 21 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.